Triển Vọng In Silico và Ứng Dụng Điều Trị của Ouabagenin và Các Chất Tương Đương Corticosteroid Hydroxyl Hóa Trong Điều Trị Ung Thư Phổi

Adami, H. O., Day, N. E., Trichopoulos, D., et al. (2001). Primary and secondary prevention in the reduction of cancer morbidity and mortality [J]. European journal of cancer, 1(37), 118–127. Ettinger, D. S., Akerley, W., Bepler, G., et al. (2010). Non–small cell lung cancer [J]. Journal of the national comprehensive cancer network, 8(7), 740–801. Iyer, S., Roughley, A., Rider, A., et al. (2014). The symptom burden of non-small cell lung cancer in the USA: A real-world cross-sectional study [J]. Supportive Care in Cancer, 22(1), 181–187. Girard, L., Zöchbauer-Müller, S., Virmani, A. K., et al. (2000). Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering [J]. Cancer research, 60(17), 4894–4906. Sun, J. M., Ahn, M. J., Ahn, J. S., et al. (2012). Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer? [J]. Lung Cancer, 1(77), 365–370. Goldstraw, P., Ball, D., Jett, J. R., et al. (2011). Non-small-cell lung cancer [J]. The Lancet., 378(9804), 1727–1740. Tripathy, D., & Camidge, R. Assessing current and emerging data sets to optimize sequencing considerations in ALK-positive NSCLC. Hematology/Oncology, 12(8), 7–32. Bose, P., & Ozer, H. (2009). Neratinib: An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer [J]. Expert opinion on investigational drugs, 18(11), 1735–51. Chan, B. A., & Hughes, B. G. (2015). Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future [J]. Translational lung cancer research, 4(1), 36. Gerber, D. E., Gandhi, L., & Costa, D. B. (2014). Management and future directions in non-small cell lung cancer with known activating mutations. American Society of Clinical Oncology Educational Book, 34(1), e353–e365. Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010). Understanding resistance to EGFR inhibitors—impact on future treatment strategies [J]. Nature reviews Clinical oncology, 7(9), 493–507. Dutta, P. R., & Maity, A. (2007). Cellular responses to EGFR inhibitors and their relevance to cancer therapy [J]. Cancer letters, 254(2), 165–177. Xu, H., Yu, Y., Marciniak, D., et al. (2005). Epidermal growth factor receptor (EGFR)–related protein inhibits multiple members of the EGFR family in colon and breast cancer cells [J]. Molecular cancer therapeutics, 4(3), 435–442. Renata, H., Zhou, Q., Dünstl, G., et al. (2015). Development of a concise synthesis of ouabagenin and hydroxylated corticosteroid analogues [J]. Journal of the American Chemical Society, 137(3), 1330–1340. Du, J., Jiang, L., Chen, F., et al. (2021). Cardiac glycoside ouabain exerts anticancer activity via downregulation of STAT3 [J]. Frontiers in oncology, 11, 2565. Tamura, S., Okada, M., Kato, S., et al. (2018). Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect [J]. Scientific reports, 8(1), 1–5. Frisch, M. J., Trucks, G. W., Schlegel, H. B., et al. (2009). Gaussian 09. Gaussian Inc. Goerigk, L., & Reimers, J. R. (2013). Efficient methods for the quantum chemical treatment of protein structures: The effects of London-dispersion and basis-set incompleteness on peptide and water-cluster geometries [J]. Journal of Chemical Theory and Computation, 9, 3240–3251. Dennington, R., Todd Keith, T., & Millam, J. (2019). GaussView, Version 6.1.1. Semichem Inc. ADMETlab 2.0 https://admetmesh.scbdd.com/. Accessed 29 Sept 2021. CcG, C. C. G. (2016). Molecular operating environment (MOE). Chem Computing Group Inc. Heinzerling, L., Klein, R., & Rarey, M. (2012). Fast force field-based optimization of protein–ligand complexes with graphics processor [J]. Journal of computational chemitry, 33(32), 2554–2565. Berman, H., Henrick. K., & Nakamura, H. (2003) Announcing the worldwide protein data bank. Nature Structural and Molecular Biology, 10, 980–980. https://www.rcsb.org/search Yaşar, Ü., Gönül, İ, Türkeş, C., Demir, Y., & Beydemir, Ş. (2021). Transition-metal complexes of bidentate Schiff-Base ligands: In vitro and in-silico evaluation as non-classical carbonic anhydrase and potential acetylcholinesterase inhibitors. ChemistrySelect [J], 6(29), 7278–7284. Al-Hazmi, G. A., Abou-Melha, K. S., El-Metwaly, N. M., et al. (2020). Green synthesis approach for Fe (III), Cu (II), Zn (II) and Ni (II)-Schiff base complexes, spectral, conformational, MOE-docking and biological studies [J]. Applied Organometallic Chemistry, 34(3), 5403. Bowers, K. J., Chow, D. E., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., Klepeis, J. L., Kolossvary, I., Moraes, M. A., Sacerdoti, F. D., & Salmon, J. K. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters. In SC'06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing (pp. 43–43). IEEE. Ferreira, L. G., Dos Santos, R. N., Oliva, G., et al. (2015). Molecular docking and structure-based drug design strategies [J]. Molecules, 20, 13384–13421. Hildebrand, P. W., Rose, A. S., & Tiemann, J. K. (2019). Bringing molecular dynamics simulation data into view [J]. Trends in Biochemical Sciences., 44, 902–913. Rasheed, M. A., Iqbal, M. N., Saddick, S., et al. (2021). Identification of lead compounds against Scm (fms10) in Enterococcus faecium using computer aided drug designing [J]. Life, 11, 77. Aziz, M., Ejaz, S. A., Tamam, N., Siddique, F., Riaz, N., Qais, F. A., Chtita, S., & Iqbal, J. (2022). Identification of potent inhibitors of NEK7 protein using a comprehensive computational approach. Scientific reports [J], 12(1), 1–17. Güleç, Ö., Türkeş, C., Arslan, M., Demir, Y., Yeni, Y., Hacımüftüoğlu, A., Ereminsoy, E., Küfrevioğlu, Ö. İ., & Beydemir, Ş. (2022). Cytotoxic effect, enzyme inhibition, and in-silico studies of some novel N-substituted sulfonyl amides incorporating 1, 3, 4-oxadiazol structural motif. Molecular Diversity, 1–21. Osmaniye, D., Türkeş, C., Demir, Y., Özkay, Y., Beydemir, Ş., & Kaplancıklı, Z. A. (2022). Design, synthesis, and biological activity of novel dithiocarbamate‐methylsulfonyl hybrids as carbonic anhydrase inhibitors. Archiv der Pharmazie, e2200132–2200145. Askin, S., Tahtaci, H., Türkeş, C., Demir, Y., Ece, A., Çiftçi, G. A., & Beydemir, Ş. (2021). Design, synthesis, characterization, in vitro and in-silico evaluation of novel imidazo [2, 1-b][1, 3, 4] thiadiazoles as highly potent acetylcholinesterase and non-classical carbonic anhydrase inhibitors. Bioorganic Chemistry [J], 113, 105009. Sever, B., Türkeş, C., Altıntop, M. D., Demir, Y., AkalınÇiftçi, G., & Beydemir, Ş. (2021). Novel metabolic enzyme inhibitors designed through the molecular hybridization of thiazole and pyrazoline scaffolds. Archiv der Pharmazie [J], 354(12), 2100294.